The trial showed that the off-the-shelf adult stem cell product Revascor increased blood supply to damaged heart muscle.
The Bottom Line: MSB’s stocks were up 85 cents, or 10.69 per cent, to $8.80 today. MSB would use the Revascor to target other vascular diseases including chronic refractory angina, Mesoblast said. It had focussed on congestive heart failure and heart attacks so far. As well as improved blood flow, the trial’s results showed long-term reduction in major adverse cardiac events, including deaths, heart attacks and heart failure. In a trial of American patients, there had been significant improvement in blood flow to the heart muscle in patients 6 months after a single injection of Revascor. Revascor could be highly effective for patients with chronic refractory angina who do not have other therapeutic options and are so debilitated by pain that their physical activity is either markedly restricted or non-existed.